Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMY757D)

Drug Name

Pelacarsen Drug Info

Indication

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Apolipoprotein A messenger RNA (LPA mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS-APO(a)	DMQ3C05	Coronary artery disease	BA80	Phase 2	[4]
AMG 890	DM3H0IX	Cardiac fibrosis	DB98.8	Phase 2	[5]
SLN360	DMVVU4V	Hyperlipidemia	5C80.Z	Phase 2	[6]
LY3819469	DMUDNNF	Elevated Lipoprotein(a)	5C80.1	Phase 2	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apolipoprotein A messenger RNA (LPA mRNA)	TTU9LGY	APOA_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04023552) A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05900141) A Single Arm, Open Label Extension (OLE), Multicenter Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Patients With Cardiovascular Disease Who Have Successfully Completed the Apheresis Parent Study.. U.S.National Institutes of Health.
3	Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022 Jul 1;7(7):760-769.
4	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
5	Clinical pipeline report, company report or official report of Amgen.
6	Recent lipoprotein(a) trials. Curr Opin Lipidol. 2022 Dec 1;33(6):301-308.
7	ClinicalTrials.gov (NCT05565742) A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a). U.S.National Institutes of Health.